Biochem/physiol Actions BAY-1797 orally available, potent and selective P2X4 antagonist that is suitable for in vivo studies in rodents. BAY-1797 exhibits potent anti-inflammatory and anti-nociceptive effects in mouse CFA inflammatory pain model.
Biochem/physiol Actions BAY-1797 orally available, potent and selective P2X4 antagonist that is suitable for in vivo studies in rodents. BAY-1797 exhibits potent anti-inflammatory and anti-nociceptive effects in mouse CFA inflammatory pain model.
Biochem/physiol Actions BAY-1797 orally available, potent and selective P2X4 antagonist that is suitable for in vivo studies in rodents. BAY-1797 exhibits potent anti-inflammatory and anti-nociceptive effects in mouse CFA inflammatory pain model.
Biochem/physiol Actions BAY-1797 orally available, potent and selective P2X4 antagonist that is suitable for in vivo studies in rodents. BAY-1797 exhibits potent anti-inflammatory and anti-nociceptive effects in mouse CFA inflammatory pain model.
BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.Target activityhuman P2X7:10.6
BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.Target activityhuman P2X7:10.6